51 Cognitive Impact of SRS vs. WBRT: Systematic Review & Meta-analysis 18. Mehta MP, Rodrigus P, Terhaard CHJ, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. Journal of Clinical Oncology 2003; 21: 2529–2536. 19. Bray VJ, Dhillon HM, Vardy JL. Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment. Journal of Cancer Survivorship 2018; 12: 537–559. 20. Hutchinson AD, Hosking JR, Kichenadasse G, et al. Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review. Cancer Treat Rev 2012; 38: 926–934. 21. Lin NU, Wefel JS, Lee EQ, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and qualityof-life outcomes. A report from the RANO group. Lancet Oncol 2013; 14: e407-16. 22. Meyers CA, Rock EP, Fine HA. Refining endpoints in brain tumor clinical trials. J Neurooncol 2012; 108: 227–230. 23. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. Journal of Clinical Oncology 2003; 21: 3557–3558. 24. Kirkpatrick JP, Wang Z, Sampson JH, et al. Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: Results of a randomized trial. Int J Radiat Oncol Biol Phys 2015; 91: 100–108. 25. Onodera S, Aoyama H, Tha KK, et al. The value of 4-month neurocognitive function as an endpoint in brain metastases trials. J Neurooncol 2014; 120: 311–319. 26. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during wholebrain radiotherapy for brain metastases (RTOG 0933): A phase II multiinstitutional trial. Journal of Clinical Oncology 2014; 32: 3810–3816. 27. Bovi JA, Pugh SL, Sabsevitz D, et al. Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933. Adv Radiat Oncol 2019; 4: 579–586. 28. Saito H, Tanaka K, Kanemoto A, et al. Factors affecting the baseline and posttreatment scores on the hopkins verbal learning test-revised Japanese version before and after whole-brain radiation therapy. Int J Mol Sci 2016; 17: 1834. 29. Chang EL, Wefel JS, Maor MH, et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007; 60: 277–283. 30. Habets EJJ, Dirven L, Wiggenraad RG, et al. Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: A prospective study. Neuro Oncol 2016; 18: 435–444. 31. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009; 10: 1037–1044. 32. Brown PD, Jaeckle K, Ballman K V., et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases a randomized clinical trial. JAMA 2016; 316: 401–409. 2
RkJQdWJsaXNoZXIy MTk4NDMw